US Bancorp’s Inhibrx INBX Stock Holding History

US Bancorp’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.88K	Sell	62 -157	-72%	-$15.7K	﹤0.01%	3608
2026 Q1	$14.7K	Buy	219 +16	+8%	+$1.19K	﹤0.01%	3223
2025 Q4	$16K	Sell	203 -14	-6%	-$954	﹤0.01%	3162
2025 Q3	$7.31K	Buy	+217	New	+$5.34K	﹤0.01%	3412
2025 Q2	–	Sell	-16	Closed	-$224	–	4243
2025 Q1	$224	Sell	16 -107	-87%	-$1.45K	﹤0.01%	4090
2024 Q4	$1.89K	Sell	123 -2,175	-95%	-$33.1K	﹤0.01%	3869
2024 Q3	$36K	Buy	2,298 +2,175	+1,768%	+$30.6K	﹤0.01%	2893
2024 Q2	$1.74K	Buy	+123	New	+$1.92K	﹤0.01%	3738

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

US Bancorp's INBX Position: Q2 2026 in Review

US Bancorp reduced its Inhibrx (INBX) stake by 72% in Q2 2026, selling an estimated $15.7K and leaving 62 shares worth $5.88K. The position accounts for ﹤0.01% of the portfolio, ranked #3608.

US Bancorp first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $36K in Q3 2024. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

US Bancorp held 62 shares of Inhibrx worth $5.88K as of Q2 2026.
US Bancorp sold 157 Inhibrx shares in Q2 2026, an estimated $15.7K.
Inhibrx made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3608 holding.
US Bancorp first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
US Bancorp's Inhibrx position peaked at $36K in Q3 2024.
163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.